Australia's most trusted
source of pharma news
Posted 25 November 2025 AM
The Federal Government has funded a compounded version of Novartis' new radiogland blockbuster Lutathera, even though it does not have TGA approval, in a bureaucratic headache caused by Australia's failing HTA processes.
While Lutathera was approved by the TGA last week, the compounded version is exempt from ARTG entry. Despite this, it won support from MSAC which recommended Government reimbursement, with the Minister giving a funding nod from 1 November. The subsidy decision is supplier agnostic so applies to the compounded version as well as Lutathera.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.